College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, PR China.
College of Science, Huazhong Agricultural University, Wuhan 430070, PR China.
Mater Sci Eng C Mater Biol Appl. 2018 Jun 1;87:155-166. doi: 10.1016/j.msec.2017.12.029. Epub 2017 Dec 29.
For successful theranosis of brain diseases, limited access of therapeutic molecules across blood-brain barrier (BBB) needs be overcome in brain delivery. Currently, peptide derivatives of rabies virus glycoprotein (RVG) have been exploited as delivery ligands to transport nanocarriers across BBB and specifically into the brain. The targeting peptides usually conjugate to the nanocarrier surface, and the cargoes, including siRNA, miRNA, DNA, proteins and small molecular chemicals, are complexed or encapsulated in the nanocarriers. The peptide ligand of the RVG-modified nanocarriers introduces the conjugated targeted-delivery into the brain, and the cargoes are involved in disease theranosis. The peptide-modified nanocarriers have been applied to diagnose and treat various brain diseases, such as glioma, Alzheimer's disease, ischemic injury, protein misfolding diseases etc. Since the targeting delivery system has displayed good biocompatibility and desirable therapeutic effect, it will raise a potential application in treating brain diseases.
为了成功治疗脑部疾病，需要克服治疗分子穿过血脑屏障（BBB）的限制，以便在脑内递药。目前，狂犬病毒糖蛋白（RVG）的肽衍生物已被用作递药配体，以将纳米载体穿过 BBB 并特异性递送至脑部。靶向肽通常连接在纳米载体表面，所载货物包括 siRNA、miRNA、DNA、蛋白质和小分子化学药物，被复合或包封在纳米载体中。RVG 修饰的纳米载体的肽配体将靶向递药引入脑部，所载货物则参与疾病治疗。肽修饰的纳米载体已被应用于诊断和治疗各种脑部疾病，如神经胶质瘤、阿尔茨海默病、缺血性损伤、蛋白质错误折叠病等。由于靶向递药系统显示出良好的生物相容性和理想的治疗效果，它将在治疗脑部疾病方面具有潜在的应用前景。
